20,407 Shares in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Acquired by Intech Investment Management LLC

Intech Investment Management LLC bought a new position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) during the third quarter, according to its most recent filing with the SEC. The firm bought 20,407 shares of the company’s stock, valued at approximately $75,000.

Other institutional investors have also recently bought and sold shares of the company. Anfield Capital Management LLC bought a new stake in Zentalis Pharmaceuticals during the 2nd quarter worth approximately $40,000. Aigen Investment Management LP purchased a new position in Zentalis Pharmaceuticals during the third quarter worth about $41,000. China Universal Asset Management Co. Ltd. grew its position in Zentalis Pharmaceuticals by 63.9% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,676 shares of the company’s stock worth $50,000 after purchasing an additional 5,333 shares in the last quarter. SG Americas Securities LLC bought a new position in shares of Zentalis Pharmaceuticals during the 2nd quarter worth approximately $58,000. Finally, Algert Global LLC bought a new position in shares of Zentalis Pharmaceuticals in the second quarter valued at approximately $78,000.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on the company. HC Wainwright reiterated a “buy” rating and set a $20.00 target price on shares of Zentalis Pharmaceuticals in a research note on Friday, November 15th. Guggenheim cut their target price on shares of Zentalis Pharmaceuticals from $12.00 to $8.00 and set a “buy” rating for the company in a research report on Friday, November 15th. Oppenheimer reiterated an “outperform” rating and issued a $20.00 price objective on shares of Zentalis Pharmaceuticals in a research note on Monday, September 16th. Finally, Wedbush upgraded Zentalis Pharmaceuticals from an “underperform” rating to a “neutral” rating and set a $4.00 price target on the stock in a research report on Monday, August 12th. Five equities research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $10.00.

Zentalis Pharmaceuticals Price Performance

Shares of Zentalis Pharmaceuticals stock opened at $3.50 on Monday. The company has a 50 day simple moving average of $3.32 and a two-hundred day simple moving average of $4.48. The firm has a market cap of $249.41 million, a PE ratio of -1.41 and a beta of 1.84. Zentalis Pharmaceuticals, Inc. has a 1 year low of $2.66 and a 1 year high of $18.07.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.56) EPS for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.36. As a group, research analysts anticipate that Zentalis Pharmaceuticals, Inc. will post -2.48 earnings per share for the current year.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.